NEW YORK -- The UK's National Institute for Health and Care Excellence on Tuesday recommended that the autologous CAR T-cell therapy brexucabtagene autoleucel (Gilead/Kite's Tecartus) be made accessible through the Cancer Drugs Fund as an option for patients with relapsed or refractory mantle cell lymphoma treated within the UK's National Health Service.